
Commentary|Videos|December 12, 2025
Odronextamab Plus CHOP Shows Early Success in Untreated DLBCL
Author(s)Jean-Marie Michot, MD
Fact checked by: Paige Britt
The Olympia-3 study explores odronextamab as a promising chemo-free treatment for untreated diffuse B-cell lymphoma patients.
In an interview with Targeted Oncology, Jean-Marie Michot, MD, Institute Gustave Roussy, discussed the details of the Olympia-3 (NCT06091865) study for patients with previously untreated diffuse large B-cell lymphoma.
The






































